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Abstract
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetically diverse HIV-1
clades have evolved, and a key question left unanswered is whether neutralizing antibodies can confer cross-clade
protection in vivo. The novel human monoclonal antibody HGN194 was isolated from an individual infected with an HIV-1
clade AG recombinant circulating recombinant form (CRF). HGN194 targets an epitope in the third hypervariable loop (V3)
of HIV-1 gp120 and neutralizes a range of relatively neutralization-sensitive and resistant viruses. We evaluated the potential
of HGN194 to protect infant rhesus monkeys against a SHIV encoding a primary CCR5-tropic HIV-1 clade C envelope. After
high-dose mucosal challenge, all untreated controls became highly viremic while all HGN194-treated animals (50 mg/kg)
were completely protected. When HGN194 was given at 1 mg/kg, one out of two monkeys remained aviremic, whereas the
other had delayed, lower peak viremia. Interestingly, all protected monkeys given high-dose HGN194 developed Gag-
specific proliferative responses of both CD4+ and CD8+ T cells. To test whether generation of the latter involved cryptic
infection, we ablated CD8+ cells after HGN194 clearance. No viremia was detected in any protected monkeys, thus ruling
out virus reservoirs. Thus, induction of CD8 T-cell immunity may have resulted from transient ‘‘Hit and Run’’ infection or
cross priming via Ag-Ab-mediated cross-presentation. Together, our data identified the HGN194 epitope as protective and
provide proof-of-concept that this anti-V3 loop mAb can prevent infection with sterilizing immunity after challenge with
virus of a different clade, implying that V3 is a potential vaccine target.
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Introduction
More than two decades after the discovery of the human
immunodeficiency virus (HIV), developing an anti-HIV vaccine
remains a crucial challenge. HIV clade C (HIV-C) comprises
approximately 56% of all cases of HIV/AIDS worldwide (www.
unaids.org) and predominates in sub-Saharan Africa, India and
China, where it is found as B’/C recombinant virus with an HIV-
C envelope. Thus, developing a safe and effective vaccine against
this most prevalent HIV-1 subtype remains an important task.
Classical prophylactic vaccine approaches that successfully
control various viral diseases are typically based upon neutralizing
antibodies (nAbs). The first attempt to develop an anti-HIV-1
vaccine involved monomeric gp120. However, broad nAbs were
not induced, and sera from vaccinated individuals failed to
neutralize most primary HIV-1 isolates [1]. Two phase III trials
using HIV-1 gp120 immunogens showed no protection [2,3].
Interest in developing nAb-based AIDS vaccines was renewed by
successful passive immunization studies in macaque models using
broadly reactive human neutralizing monoclonal antibodies
(bnmAbs) against challenge with chimeric simian-human immu-
nodeficiency viruses (SHIVs) encoding HIV-1 envelope genes in
an SIV backbone [4–12]. These studies provided proof-of-concept
that full protection against primate immunodeficiency virus
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18207challenge could be achieved with bnmAbs targeting conserved,
functionally important HIV-1 Env epitopes.
Initially, antibodies isolated from HIV-1 clade B-infected
individuals targeting the third variable loop (V3) of HIV-1
gp120 were thought to be narrowly focused and strain-specific,
due to high V3 sequence variability. However, V3 contains
conserved structural elements involved in crucial interactions with
coreceptors [13]; indeed, the V3 loop crown is thought to be
organized into a folded domain that forms the basis for the cross-
reactivity of some V3-specific mAbs, including 447-52D, 2219,
3014 and HGN194 [14]. Moreover, two potent bnmAbs, PG9 and
PG16, have been discovered recently; both target highly
conformational, discontinuous epitopes involving the V2 and V3
loops [15]. These data highlight the importance of V3 as target for
broadly reactive nAbs.
The human anti-V3 mAb, HGN194 [16], isolated from
memory B cells of a long-term non-progressor infected with a
HIV-1 clade AG circulating recombinant form (CRF), targets an
epitope in the V3-loop crown and neutralizes a range of relatively
neutralization-sensitive and resistant viruses from clades A, B, C as
well as recombinant AG and BC [16]. In this study, the IgG1 mAb
HGN194 neutralized all tier 1 viruses, which are highly
neutralization sensitive, and 11% of the tier 2 viruses tested. Tier
2 strains are more difficult to neutralize and reflect the majority of
primary HIV-1 isolates.
Here, we evaluated the potential of HGN194 to protect rhesus
monkeys(RM)against mucosalchallengewith aheterologousSHIV
encoding a CCR5-tropic (R5) HIV-C envelope. We found that at a
high nmAb dose, all animals were completely protected, indicating
for the first time potent cross-clade protection by a human anti-
HIV-1 mAb in vivo. Interestingly, all SHIV-challenged RM treated
with high-dose HGN194 developed Gag-specific T-cell immunity,
although we found no evidence of virus reservoirs after HGN194
had cleared and the CD8+ cells were ablated with a cytotoxic mAb
in protected RM. Thus, passive immunization with HGN194 is to
our knowledge the first study that provided evidence of complete
cross-clade protection.
Results and Discussion
Given the diversity of V3 amino-acid sequences of viruses
neutralized by HGN194 [16], we hypothesized that HGN194
recognizes a conformational epitope in the V3 crown. We thus
evaluated HGN194 binding to gp120 and gp160 under native and
reduced conditions (Figure 1). Compared to native Env, HGN194
binding was clearly decreased when either gp120 or gp160 were
denatured, indicating conformation dependence of the HGN194
epitope.
We then evaluated the ability of HGN194 to neutralize a panel
of R5-tropic SHIVs with different neutralization sensitivity in
vitro (Table 1). SHIV-1157ipd3N4 is a ‘‘late’’, tier 2 virus derived
from a monkey after it developed AIDS [17], whereas SHIV-
1157ipEL-p [18] is a chimera of the ‘‘early’’ SHIV-1157ip env
(derived from a recently infected Zambian infant’s primary R5
HIV-C) and the ‘‘late’’, engineered backbone of SHIV-
1157ipd3N4. The final SHIV-1157ipEL-p chimera was derived
by rapid passage through four rhesus macaques for adaptation
and has a tier 1 neutralization phenotype [18]. SHIV-
1157ipd3N4 and SHIV-1157ipEL-p are isogenic forms of the
same virus, differing only in the nature of their R5 HIV-C Envs.
SHIVSF162P4 was derived from an R5 clade B HIV-1 and has a
tier 1 neutralization-sensitive profile [19].
Figure 1. HGN194 targets a unique conformational V3-loop epitope. Plasma from monkey RMf-9 (white bars with black dots), chronically
infected with SHIV-1157ip, was used as positive control as well as 2G12 (grey bars), a mAb targeting a conformational mannose-dependent epitope
on gp120. Herceptin (white bars) and plasma from naı ¨ve monkey RMj-2 (striped bars) were used as negative controls. Results of conformational ELISA
are shown. Additional control studies have been published earlier [24].
doi:10.1371/journal.pone.0018207.g001
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SHIVSF162P4 in vitro at low 50 and 90% inhibitory concentrations
(IC50 and IC90, respectively). However, it failed to neutralize the
tier 2 SHIV-1157ipd3N4 (Table 1).
Next, we sought to test the efficacy of HGN194 in vivo and
enrolled two groups of infant RM. Group 1A (n=4) was treated
with HGN194 at 50 mg/kg. Group 2 control monkeys (n=4)
were left untreated. MAb treatments were given 24 h before and 7
days after virus challenge (Figure 2A). On day zero, all monkeys
were challenged intrarectally with a high dose of SHIV-1157ipEL-
p (18 50% animal infectious doses (AID50)). All controls (Group 2)
became highly viremic with a mean peak viral RNA load of
8.6610
663.1610
6 copies/ml at week 2 (Figure 2B); in contrast,
all infants of Group 1A remained aviremic throughout the course
of the study. Western blots were positive for SIV Gag in all
controls but negative in all Group 1A monkeys (data not shown).
Similarly, lymph node biopsies (week 10) were negative for all four
Group 1A infants but highly positive for Group 2 monkeys when
tested by RT-PCR specific for SIV gag (Figure S1B). We conclude
that HGN194, isolated from an HIV-positive individual harboring
an AG CFR, was able to confer complete cross-clade protection
against a clade C SHIV.
To estimate the minimal effective dose required for full
protection, we performed a pilot study with Group 1B (n=2)
that received a 50-fold lower HGN194 dose. One animal (RNc-13)
remained aviremic, while the second animal, ROa-13, became
infected but showed a.100-fold lower peak viremia which was
delayed by 2 weeks compared to controls (Figure 2B). Animal
ROa-13 developed anti-SIV Gag antibodies, while RNc-13 did
not (data not shown).
The animals were followed prospectively by clinical examina-
tion and analysis of T-cell subsets. HGN194 was well tolerated
without obvious side effects. The absolute CD4 T-cell counts of
the virus-exposed, uninfected animals of Group 1A and monkey
RNc-13 showed normal, age-related declines also seen in human
infants. At week 23, SHIV-1157ipEL-p-viremic controls had lower
CD4 T-cell counts compared to mAb-treated, uninfected animals
(Figure S1A).
Next, we sought to link nAb titers achieved in vivo with the
degree of protection. First, we assessed HGN194 plasma
concentrations by ELISA in mAb-treated monkeys. In Group
1A, the average HGN194 concentration was 213.7 mg/ml on the
day of challenge (Figure 2C). HGN194 followed a biphasic decay
with a mean half-life of 24.665.3 h in the first phase and a mean
half-life of 31.469.2 days in the second phase. In Group 1B, the
average HGN194 concentration on the day of challenge was
11.1 mg/ml (Figure 2D), which approximated the in vitro IC90
(10.8 mg/ml) observed in the TZM-bl neutralization assay with
purified HGN194 in vitro (Table 1). Second, we measured the
neutralizing capacity of monkey plasmas by TZM-bl assay against
the challenge virus (SHIV-1157ipEL-p). When IC50 and IC90
values from individual monkeys were plotted against the plasma
HGN194 concentrations, a correlation with IC50 (p=0.0002) and
IC90 (p=0.0012) was observed in Group 1A (data not shown).
From these data, we extrapolated an average in vivo IC50 of
0.2 mg/ml and an average in vivo IC90 of 2.15 mg/ml – values that
were in the same order of magnitude as the initial in vitro IC50
(0.6 mg/ml) and IC90 (10.8 mg/ml) obtained by TZM-bl assay
against the challenge virus (Table 1). These data suggest a direct
relationship between the in vitro inhibitory concentrations and
protection from challenge in an in vivo model. This result is in
accordance with the recent finding that mAb 2G12 serum
neutralizing titers of the order of 1:1 (IC90) can protect animals
with sterilizing immunity and contrasts strongly with the high titers
needed for protection by other nAbs, including the bnmAb b12
[11]. This may be linked to the lack of autoreactivity of both
HGN194 and 2G12 [20] (Figure S2) and/or differences in the
mechanisms of neutralization.
We then sought to test whether the macaques protected by
passive immunization had developed antiviral cellular immune
responses, given the likely development of antigen-antibody
complexes. We performed interferon-c ELISPOT assays after
stimulation of PBMC with SIV Gag, Nef and HIV-1 Tat peptides,
as well as T-cell proliferative assays by CFSE dilution after
stimulation with SIV Gag and HIV-1 Env and Tat proteins. All
mAb-treated animals were ELISPOT negative, in contrast to
Group 2 controls (3 out of 4 RM had total spot-forming units
ranging from 130 to 480/million cells; data not shown). However,
all Group 1A monkeys showed proliferation of CD4
+ as well as
CD8
+ T cells after stimulation with SIV Gag (Figure 3A) but not
with HIV-1 Env and Tat proteins (data not shown), suggesting that
specific memory T cells developed only against the most abundant
virion protein, SIV Gag. Of note, all RM of the virus-only control
Group 2 also had proliferative responses in the CD4+ and CD8+
T-cell populations, although the levels differed among the
individual monkeys (Figure 3A). Next, we tested Group 1B, which
had received a 50-fold lower HGN194 dose, for proliferative T-
cell responses to viral proteins; no T-cell responses to any viral
proteins were detectable (Figure 3B). Thus, only RM exposed to
virus in the context of a high but not a low nmAb dose developed
Gag-specific proliferative responses of both CD4+ and CD8+ T
cells.
The following mechanisms may have induced virus-specific
CD8+ T cells in the persistently aviremic monkeys: a) cryptic
Table 1. Neutralization of clade B and C SHIV strains in TZM-bl and human PBMCs.
TZM-bl-based assay PBMC-based assay
Virus Tier
a HGN194 epitope HGN194 (mg/ml) 4X (mg/ml)
b HGN194 (mg/ml) 4X (mg/ml)
b
V3 sequence IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
HIV CRF02_AG
c 2 RRSVRIGPGQTF N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A.
SHIVSF162P4 1 RKSITIGPGRAF 0.2 1.6 7.8 31.5 ,0.04 1.3 0.8 15.8
SHIV-1157ipEL-p 1 RKSIRIGPGQAF 0.6 10.8 36 .40 0.01 0.09 0.9 .40
SHIV-1157ipd3N4 2 RKSISIGPGQAI .40 .40 .40 .40 .40 .40 8.2 .40
aNeutralization tier assignment.
b4X, quadruple combination of IgG1b12, 2G12, 2F5, and 4E10 at 1:1:1:1 ratio.
cParental virus that was not available for testing. The epitope is given for comparison.
doi:10.1371/journal.pone.0018207.t001
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infectious after loss of immune control; b) transient, cryptic ‘‘Hit
and Run’’ infection without reservoir cells but providing sufficient
antigen exposure to generate specific cellular immunity; or c)
cross-presentation of antigen-antibody complexes in the absence of
target cell infection [21].
To test for the possibility of virus-producing reservoir cells, we
depleted CD8+ T and NK cells with a rhesus anti-CD8 mAb in
all Group 1A and 1B monkeys after HGN194 plasma
concentrations had declined below the IC50. A rapid drop of
CD8+ T cells was accompanied by a rise in viremia for ROa-13,
the Group 1B monkey that initially had delayed lower viremia
(Figure 3C and 3D). In contrast, all protected monkeys from
Groups 1A and 1B remained aviremic after CD8+ cell depletion,
indicating that no viral reservoir capable of releasing virus
existed. Currently, we cannot differentiate between a transient
cryptic ‘‘Hit and Run’’ infection that resolved without leaving
behind any infected reservoir cells or cross-presentation of
antigen-antibody complexes, although the latter is an attractive
hypothesis, especially in light of the fact that Group 1B monkeys
had not developed any T-cell proliferative responses. This might
be ascribed to lower levels of antigen-antibody complexes formed
after treatment with the 50-fold lower HGN194 dose compared
to Group 1A RM.
In general, in vitro neutralization assays reflect inhibition of
viral entry. However, nmAb effector functions, such as antibody-
dependent cellular cytotoxicity (ADCC) or complement activation,
may also contribute to the overall antiviral activity in vivo. Effector-
deficient mAb mutants have been used to demonstrate the
importance of these mechanisms in macaques [12]. ADCC
activity of HGN194, an IgG1 nmAb, may have contributed to
the complete protection from systemic infection in our study –
perhaps via eradication of small numbers of infected target cells,
thus allowing a ‘‘Hit and Run’’ transient infection that primed T-
cell immunity. Passive immunization studies with effector
function- deficient HGN194 mutants would assess the relative
contribution of standard virus neutralization versus mAb effector
functions to the protective action of HGN194.
In summary, we have shown that HGN194, an nmAb targeting
a unique conformational epitope, can confer complete protection
against a heterologous, high-dose mucosal clade C SHIV
challenge in macaques. These results identify the HGN194 target
as a protective epitope in vivo and a potential vaccine target for
cross-clade immunization.
Figure 2. Passive immunization with HGN194 against heterologous clade C SHIV challenge in infant rhesus macaques. (A)
Experimental design. Group 1A infant RM (n=4) were infused twice with 50 mg/kg of HGN194 on days 21 and 7. Group 1B (n=2) received twice
1 mg/kg of HGN194. Four RM served as untreated controls. On day 0, all 10 animals were challenged intrarectally with 18 AID50 of SHIV-1157ipEL-p.
(B) Plasma viral RNA loads after high-dose rectal challenge with SHIV-1157ipEL-p using a quantitative RT assay (detection limit: 50 copies/ml). (C)
Average plasma mAb concentrations during the course of the study for Group 1A. (D) Plasma HGN194 concentration for Group 1B. Arrows in C and D
indicate mAb treatments. Experiments in C and D were repeated twice or trice.
doi:10.1371/journal.pone.0018207.g002
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Cell lines, viruses and antibodies
TZM-bl cells were purchased from the NIH AIDS Research
and Reference Reagent Program (ARRRP). HGN194 was
prepared as described [16]. The SHIV-1157ipEL-p stock (grown
in RM PBMC) had a p27 concentration of 50 ng/ml and 1.5x10
5
50% tissue culture infectious doses (TCID50)/ml as measured in
TZM-bl cells.
In vitro neutralization assays
Heat-inactivated, serially diluted plasmas/antibodies were incu-
bated with virus for 1 h at 37uC and then added to cells. The TZM-
bl assay was performed as described [22]. PBMC assays were
performed as published [23], except that polymyxin B (15 mg/ml)
was added to block potentially present endotoxin. Throughout the
assay, the mAbs were not washed away but diluted 1:1 with fresh
medium daily, starting on day 3. Supernatant aliquots were
harvested every other day and assayed for p27 levels in wells
containing only virus+cells. Neutralization was measured on the
culture day showing a linear phase of increase in control wells.
Conformational ELISA
ELISA was performed as described [24] with modifications.
Plates were coated with 40 ng/well of native or reduced (20 mM
TCEP/0.4% SDS; boiled for 5 min) proteins and the next day
washed, blocked and incubated overnight at 4uC with 100 ml/well
of either HGN194, Herceptin, 2G12 (5 mg/ml in PBSCT) or RM
serum (1:400; 100 ml/well diluted in PBSCT). After washing,
plates were incubated with HRP-conjugated antibodies, washed
10 times, developed and read at 490/620 nm.
Animal care and passive immunization
This study was carried out in strict accordance with the
r e c o m m e n d a t i o n si nt h eG u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r y
Animals of the U.S. Public Health Services/National Institutes of
Health, as well as according to the recommendations in the
Weatherall report on ‘‘The Use of Non-human Primates in
Research’’ (http://www.acmedsci.ac.uk/images/project/nhpdownl.
pdf). The protocol was approved by the Committee on the Ethics of
Animal Experiments of Emory University (IACUC ID: 027-2009Y;
Emory University Animal Welfare Assurance Number A3180-01).
The rhesus monkeys were housed at the Yerkes National Primate
Research Center (YNPRC, Emory University, Atlanta, GA).
YNPRC facilities are fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional. Animal experiments were approved by the Institutional
Animal Care and Use Committees at Emory and the Dana-Farber
Cancer Institute via a Collaborating Institution Animal Use
Agreement. Because the experiments described here involved a virus
Figure 3. Induction of specific antiviral T-cell responses after passive immunization. (A) and (B) Proliferation of T cells. PBMC were
stimulated with SIVmac251 Gag protein and proliferation of CD4
+ and CD8
+ cells was measured using the CFSE dilution method. (A) Animals given
50 mg/kg of HGN194 (Group 1A) and control group RM (Group 2). PBMC collected 17 weeks post-challenge were tested. Horizontal dashed line, cut-
off value based on response shown by a naı ¨ve animal. (B) Animals given 1 mg/kg of HGN194 (Group 1B). PBMC collected at weeks 12 (RNc-13) and 17
(ROa-13) post-challenge were tested. (C) Absolute numbers of CD8+ T cells for Groups 1A (black) and 1B (grey) after treatment with a cytotoxic anti-
CD8 mAb (Methods). (D) Plasma viral RNA load after CD8+ cell depletion.
doi:10.1371/journal.pone.0018207.g003
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and pain may occur. Animals were closely monitored and observed
for development of disease at least twice daily. If the animals are
determined to be under stress or in discomfort, appropriate
anesthetics and/or analgesics are administered as directed by the
clinical veterinary staff. Euthanasia is also an option should treatment
not alleviate stress. In the current study, no untoward clinical
problems were noted, and none of the virus-infected monkeys
progressed to AIDS.
Four RM received two i.v. doses of HGN194 (50 mg/kg); two
monkeys received 1 mg/kg. Four untreated animals served as
controls. All monkeys were challenged intrarectally with 18 50%
animal infectious doses (AID50) of SHIV-1157ipEL-p.
Assessment of plasma viral RNA levels
Plasma viral RNA levels were measured as described [18,25].
Lymphocyte proliferation assay
The assay was performed as described [26]. In brief, PBMC
were stained with CFSE and incubated with/without antigen (SIV
Gag, HIV-1 Tat or SHIV-1157ip gp160; 2 mg/ml) for 5 days at
37uC. Cells were stained with anti-CD3-Alexa Fluor 700 (clone
SP34-2), anti-CD4-PerCP (clone L200) and anti-CD8-PE (clone
RPA-T8) antibodies. The percentage of proliferating CD3
+CD4
+
and CD3
+CD8
+ cells was determined using FACSDiva (BD
Biosciences) software.
Anti-CD8 antibody administration
M-T807R1 (Nonhuman Primate Reagent Resource, Beth Israel
Deaconess Medical Center, Boston, MA), a primatized anti-CD8
mAb, was administered subcutaneously (50 mg/kg) on day 0.
MAb administration was initiated 7 months after SHIV-
1157ipEL-p challenge for Group 1A, while monkeys ROa-13
and RNc-13 (Group 1B) were given mAb at 5.5 and 4 months
post-challenge, respectively.
HGN194 plasma concentration
HGN194 plasma concentrations were determined by ELISA.
Nunc 96-well plates were coated with gp120 of SHIV-1157ip
(2 mg/ml) and incubated overnight at 4uC. After blocking and
washing, serially diluted plasmas were added. HGN194 was
included as standard ranging from 1.5 to 0.046 ng/ml. After
washing, plates were incubated 1 h with an anti-human IgG HRP
antibody (Zymed, San Francisco, CA). After washing, HRP
substrate (Rockland Immunochemicals, Gilbertsville, PA) was
added and after 30 min, the reaction was stopped with 1 N
sulfuric acid and the OD was measured at 450 nm with a
microplate reader (Berthold, Oak Ridge, TN). To determine the
half-life of HGN194, natural logs of HGN194 plasma levels were
plotted as a function of time from the end of infusion. Slopes of the
linear graphs were determined by least-squares analysis. Half-lives
were calculated as t1/2=2(ln 2)/m.
Statistical analysis
Statistical analyses were performed using Graph Pad Prism for
Windows, version 5 (Graph Pad Software Inc., San Diego, CA).
Supporting Information
Figure S1 Absolute CD4+ T cells and lymph node
biopsies. (A) Absolute CD4 T cell counts. From week 23
onward, the SHIV-1157ipEL-p-infected control monkeys showed
decreased CD4 T-cell counts compared to uninfected animals. (B)
Lymph node biopsies (week 10) were negative for all four Group
1A infants but highly positive for Group 2 monkeys when tested by
RT-PCR specific for SIV gag. Black bars, RT-PCR performed
with 1 mg of RNA per reaction; stippled grey bars, 0.25 mgo f
RNA per RT-PCR test.
(TIF)
Figure S2 HGN194 lacks of autoreactivity. MAbs were
tested for their autoreactivity by indirect immunofluorescence
using the Biochip mosaic diagnostic assay (Euroimmun, Ger-
many). All mAbs were tested at 10 mg/ml using Hep-20-10 cells
for antinuclear antibodies, primate liver for antibodies directed
against liver-specific proteins and liver-cell membranes, rat kidney
for antibodies targeting kidney microsomes or mitochondria, and
rat stomach for antibodies binding to smooth muscle. MAb 2F5
was included because Haynes et al. [16] demonstrated its
autoreactivity. In the same study, 2G12 had no evidence of
autoreactivity. In contrast to 2F5, 2G12 was found to have a long
half-life (Armbruster C, et al. A phase I trial with two human
monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS
2002; 16: 227–233). In Figure S2, mAbs 2G12 and HGN194 did
not show autoreactivity, while the mAb 2F5 did. The irregular
staining in monkey liver sections is considered non-specific.
(TIF)
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